BackgroundEnteral nutrition (EN) is essential for Inflammatory Bowel Disease treatment. This applies mainly to Crohn’s disease (CD) and ulcerative colitis (UC) patients. The study evaluated the impact of EN treatment on clinical, nutritional, inflammatory, and quality of life outcomes in IBD patients. This study aimed to examine the association between EN therapy’s clinical, nutritional, inflammatory, and Quality of Life (QoL) effects on Inflammatory Bowel Disease patients.MethodsA retrospective study investigated 750 Chinese IBD patients. These patients had 400 CD and 350 UC diagnoses. Medical records provided data. EN formula, administration, calorie density, and duration were studied along with disease activity, nutritional markers including hemoglobin, albumin, and body mass index, and inflammatory indices like erythrocyte sedimentation rate. Validated IBDQ measures quality of life. Clinical remission was defined as a Crohn’s Disease Activity Index (CDAI) score 1) for UC patients, assessed after completion of EN therapy. Chi-square and t-tests were used for statistical analysis, with a significance level of p 6 weeks) were independently associated with higher odds of remission and QoL improvement.ConclusionEN therapy corresponded with clinical remission, improved nutritional markers, and reduced inflammation in IBD patients, particularly those with CD. These findings support the potential role of EN as a complementary strategy in IBD management; however, prospective randomized trials are further confirming these associations and standardize therapeutic protocols.
Chen et al. (Wed,) studied this question.